文献速递糖尿病

亚组Meta分析与临床解读的方法学框架:2型糖尿病中GLP-1受体激动剂与SGLT2抑制剂主要不良心血管事件的案例

A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2024-01-01

本文提出一个用于开展和解读亚组Meta分析的方法学框架,包括评估亚组定义临床异质性、评价亚组Meta分析可信度及将相对效应转化为绝对效应。以2型糖尿病心血管结局试验中GLP-1受体激动剂和SGLT2抑制剂亚组数据为例,按已确诊心血管疾病与无心血管疾病高危分层,结果建议两个亚组使用相同的总体相对效应。

要点

  • 方法学框架包括异质性评估、可信度评价和相对转绝对效应。
  • 建议两个亚组使用相同的总体相对效应:GLP-1受体激动剂HR 0.85,SGLT2抑制剂HR 0.91。
  • 5年绝对效应:GLP-1受体激动剂在已确诊心血管疾病亚组每1000人减少30例事件,无心血管疾病亚组减少14例。

核心结论

  • 结果建议两个亚组(已确诊心血管疾病与无心血管疾病高危)使用相同的总体相对效应。

研究设计与样本

  • 方法学框架研究,使用2型糖尿病心血管结局试验(CVOTs)中GLP-1受体激动剂和SGLT2抑制剂的亚组数据。

主要发现

  • 以安慰剂组MACE发生率作为基线心血管风险代理指标,各CVOTs间基线风险无显著差异。
  • GLP-1受体激动剂MACE的HR为0.85(95% CI 0.80-0.90)。
  • SGLT2抑制剂MACE的HR为0.91(95% CI 0.85-0.97)。
  • 5年绝对效应:GLP-1受体激动剂在已确诊心血管疾病亚组每1000人减少30例事件,无心血管疾病亚组减少14例。
  • 5年绝对效应:SGLT2抑制剂在已确诊心血管疾病亚组每1000人减少18例事件,无心血管疾病亚组减少8例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a methodological framework for conducting and interpreting subgroup meta-analyses. Methodological steps comprised evaluation of clinical heterogeneity regarding the definition of subpopulations, credibility assessment of subgroup meta-analysis, and translation of relative into absolute treatment effects. We used subgroup data from type 2 diabetes cardiovascular outcomes trials (CVOTs) with glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors for patients with established cardiovascular disease and those at high cardiovascular risk without manifest cardiovascular disease. First, we evaluated the variability in definitions of the subpopulations across CVOTs using major adverse cardiovascular events (MACE) incidence in the placebo arm as a proxy for baseline cardiovascular risk. As baseline risk did not differ considerably across CVOTs, we conducted subgroup meta-analyses of hazard ratios (HRs) for MACE and assessed the credibility of a potential effect modification. Results suggested using the same overall relative effect for each of the two subpopulations (HR 0.85, 95% CI 0.80-0.90, for GLP-1 receptor agonists and HR 0.91, 95% CI 0.85-0.97, for SGLT2 inhibitors). Finally, we calculated 5-year absolute treatment effects (number of fewer patients with event per 1,000 patients). Treatment with GLP-1 receptor agonists resulted in 30 fewer patients with event in the subpopulation with established cardiovascular disease and 14 fewer patients with event in patients without manifest cardiovascular disease. For SGLT2 inhibitors, the respective absolute effects were 18 and 8 fewer patients with event per 1,000 patients. This framework can be applied to subgroup meta-analyses regardless of outcomes or modification variables.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Karagiannis T, Tsapas A, Bekiari E, et al. A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes. Diabetes Care. 2024. PMID: 38241493. doi:10.2337/dc23-0925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。